Latest News for: jnj

Edit

Was The Run In JNJ Stock Hiding In Plain Sight (Insight Guru Inc)

Public Technologies 30 Sep 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134838796) .
Edit

$85 Billion And Counting: JNJ Stock’s Steady Cash-Return Habit (Insight Guru Inc)

Public Technologies 28 Sep 2026
With Johnson & Johnson (JNJ) stock up 57% over the last twelve months, what did owners actually get beyond the share price? The answer is an extraordinary river of cash ... The question of why JNJ ...
Edit

Why Is JNJ Stock Beating Rivals That Grow Faster (Insight Guru Inc)

Public Technologies 22 Sep 2026
). Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six ... JNJ PFE MRK LLY ABBV MDT ... PE Ratio 31.0 38.2 115.0 38.8 74.1 22.4.
Edit

Should You Judge JNJ Stock Without STELARA (Insight Guru Inc)

Public Technologies 16 Sep 2026
). Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price ... The exclusion is not a rounding adjustment.
Edit

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer (Nanobiotix SA)

Public Technologies 14 Sep 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

CONTINEUM THERAPEUTICS REPORTS PHASE 2 RESULTS FOR JNJ-5120/PIPE-307 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (Form 8-K) (Contineum Therapeutics Inc)

Public Technologies 14 Sep 2026
) CONTINEUM THERAPEUTICS REPORTS PHASE 2 RESULTS FOR JNJ-5120/PIPE-307 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ... JNJ-5120/PIPE-307 was well-tolerated with no new safety signals. JNJ-5120/PIPE-307 ...
Edit

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer (Form 6-K) (Nanobiotix SA)

Public Technologies 14 Sep 2026
In this study, JNJ-1900 (NBTXR3) was delivered without dose-limiting toxicities, and we observed clinically meaningful local control at a substantially lower re-irradiation dose ... About JNJ-1900 (NBTXR3).
Edit

JNJ Stock: Is the Rally Running Out of Steam (Insight Guru Inc)

Public Technologies 10 Sep 2026
) ... Johnson & Johnson (JNJ), the healthcare company whose products span from advanced cancer therapies to surgical robotics, has been on a tear ... But the pace has suddenly slowed ... This pause puts every potential buyer on the spot ... companies ... Disclaimer.
Edit

How Will JNJ Stock React To Its Upcoming Earnings (Insight Guru Inc)

Public Technologies 14 Jul 2026
) How Will JNJ Stock React To Its Upcoming Earnings? ... JNJ ... Johnson & Johnson (NYSE.JNJ) is set to report its earnings on Wednesday, July 15, 2026 ... Relevant Articles JNJ Stock Keeps Climbing ... JNJ Earnings Dates JNJ ABBV.
Edit

JNJ Stock Keeps Climbing. Should You Climb On (Insight Guru Inc)

Public Technologies 10 Jul 2026
Johnson & Johnson (JNJ) develops and sells a vast portfolio of pharmaceuticals and medical devices, from cancer therapies to surgical tools ... JNJ's performance is driven by more than a market updraft ... 6.5 for JNJ versus 3.3 for the market median.
Edit

Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

Morgan Citizen 09 Jul 2026
Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day ... .
  • 1

Article Search

tools
×
×
×
×